Clinical trialNCT04494646CompletedPhase 2Interventional

BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)

SponsorNYU Langone HealthEnrollment40Covid19

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This multi-center, double-blind, placebo-controlled, randomized Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in patients hospitalized with confirmed COVID-19. The trial will include approximately 40 patients and is designed to provide an early interim analysis of safety. Patients will be randomized using permuted block randomization in a 1:1 fashion to either once-daily administration of bardoxolone methyl (20 mg) or matching placebo and treatment will be administered for the duration of hospitalization (until recovery), with a maximum treatment duration of 29 days.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sripal Bangalore, MD, MHA
NYU Langone Health
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Hshs St. John'S Hospital (prairie Education and Research Cooperative)
Springfield, Illinois, United States
Siu School of Medicine
Springfield, Illinois, United States
Coney Island Hospital
Brooklyn, New York, United States
Nyu Langone Hospital - Brooklyn
Brooklyn, New York, United States
Elmhurst Hospital Center
Elmhurst, New York, United States
Nyu Winthrop Hospital
Mineola, New York, United States
Nyu Bellevue Hospital Center
New York, New York, United States
Nyu Langone Health
New York, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bardoxolone methylPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Sept 2020
Primary completion: 8 Jan 2021
Completion: 8 Jan 2021
Last update posted: 13 Jan 2022
Registered enrollment: 40
Registry id: NCT04494646

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.